Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Osteosarcoma

ClinicalTrials.gov lists 598 trials for Osteosarcoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 67.

MeSH D012516 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 149 Phase 1/2 Phase 1/2 69 Phase 2 Phase 2 195 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 18 Phase 4 Phase 4 2 Not applicable Not applicable 45 Observational Observational 107 Phase 1 Phase 1 149 Phase 1/2 Phase 1/2 69 Phase 2 Phase 2 195 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 18 Phase 4 Phase 4 2 Not applicable Not applicable 45 Observational Observational 107

Trials per phase (log scale)

1 more section with rows

467 of the 598 trials are tagged with Osteosarcoma itself; the rest are tagged with a narrower condition beneath it.

Get the Osteosarcoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Osteosarcoma trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 41

1990: 1 trials (Phase 2 1) 1992: 2 trials (Observational 1, Phase 2 1) 1993: 1 trials (Phase 2 1) 1994: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 1995: 1 trials (Phase 1 1) 1996: 5 trials (Phase 2 5) 1997: 5 trials (Not applicable 1, Phase 2 2, Phase 1 2) 1998: 6 trials (Observational 2, Phase 2 2, Phase 1 2) 1999: 9 trials (Phase 2 6, Phase 1/2 1, Phase 1 2) 2000: 10 trials (Observational 3, Phase 2 2, Phase 1/2 1, Phase 1 4) 2001: 12 trials (Observational 1, Phase 2 6, Phase 1 5) 2002: 7 trials (Observational 2, Phase 2 3, Phase 1 2) 2003: 7 trials (Observational 2, Not applicable 1, Phase 2 4) 2004: 8 trials (Observational 1, Phase 2 4, Phase 1 3) 2005: 11 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 1/2 1, Phase 1 6) 2006: 10 trials (Not applicable 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2007: 21 trials (Observational 3, Not applicable 1, Phase 3 2, Phase 2 10, Phase 1/2 1, Phase 1 4) 2008: 20 trials (Observational 5, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 3) 2009: 18 trials (Observational 4, Phase 3 2, Phase 2 8, Phase 1/2 1, Phase 1 3) 2010: 23 trials (Observational 10, Phase 3 2, Phase 2 2, Phase 1/2 2, Phase 1 7) 2011: 15 trials (Observational 2, Not applicable 1, Phase 2 7, Phase 1 5) 2012: 13 trials (Not applicable 3, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2013: 16 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 6, Phase 1/2 3, Phase 1 4) 2014: 25 trials (Observational 7, Not applicable 2, Phase 3 1, Phase 2 8, Phase 1/2 1, Phase 1 6) 2015: 12 trials (Observational 1, Not applicable 2, Phase 2 5, Phase 1/2 2, Phase 1 2) 2016: 21 trials (Not applicable 1, Phase 2/3 2, Phase 2 8, Phase 1/2 2, Phase 1 8) 2017: 27 trials (Observational 7, Phase 2 14, Phase 1/2 4, Phase 1 2) 2018: 36 trials (Observational 10, Not applicable 3, Phase 3 1, Phase 2 9, Phase 1/2 6, Phase 1 7) 2019: 23 trials (Observational 7, Not applicable 1, Phase 2 6, Phase 1/2 2, Phase 1 7) 2020: 28 trials (Observational 6, Not applicable 5, Phase 2 8, Phase 1/2 2, Phase 1 7) 2021: 38 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 9, Phase 1/2 8, Phase 1 7) 2022: 27 trials (Observational 4, Not applicable 4, Phase 3 1, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 6) 2023: 28 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 6, Phase 1/2 6, Phase 1 10) 2024: 41 trials (Observational 7, Not applicable 2, Phase 2 15, Phase 1/2 7, Phase 1 10) 2025: 21 trials (Observational 7, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1/2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 31
2025 21
2024 41
2023 28
2022 27
2021 38
2020 28
2019 23
2018 36
2017 27

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 38 trials starting in 2026 and about 30 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 86 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 329 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Osteosarcoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 149
Phase 1/2 69
Phase 2 195
Phase 2/3 6
Phase 3 18
Phase 4 2
Not applicable 45
Observational 107
Expanded access 7

How many Osteosarcoma trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 21
Recruiting 112
Enrolling by invitation 1
Active, not recruiting 49
Available 2

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Osteosarcoma trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 67
Children's Oncology Group 32
Italian Sarcoma Group 10

Which drugs are being tested for Osteosarcoma? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 32
Irinotecan 22
TOPOTECAN 11
Calcium Leucovorin 11
NIVOLUMAB 9

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ifosfamid 30
Doxorubicine 29
Etoposid 22
SOC: Temozolomide 21
Cisplatin 1 19

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Osteosarcoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 138 27
Anemia 135 23
Lymphocyte count decreased 115 13
Pleural effusion 113 40
Platelet count decreased 105 22

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Osteosarcoma? (322)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Comparison of oncological and functional outcomes in Lower-limb osteosarcoma pediatric patients: a large single-center retrospective cohort study. International journal of surgery (London, England) 2024 Yes
Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2024 Yes
A Systematic Review of the Gonadotoxicity of Osteosarcoma and Ewing's Sarcoma Chemotherapies in Postpubertal Females and Males. Journal of adolescent and young adult oncology 2024 Yes
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA oncology 2024 Yes

Showing 5 of 322 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (8)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Osteosarcoma Annual incidence 1-9 / 1 000 000 United States US Exact
Osteosarcoma Annual incidence 1-9 / 1 000 000 United States US Exact
Osteosarcoma Point prevalence 1-9 / 100 000 Europe Not stated Exact
Osteosarcoma Lifetime prevalence 1-9 / 100 000 Europe Not stated Exact
Osteosarcoma Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Showing 5 of 8 prevalence observations.

Start your 14-day trial Email me all 8 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Osteosarcoma 668 Exact Orphanet Rare Disease Ontology (ORDO)
Osteosarcoma 668 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages